Professor Isa Odidi is a founder and one of the principals of IntelliPharmaCeutics, and serves as Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer and Chair of Scientific Advisory Board.

From 1995 to 1998, Professor Isa Odidi held positions, first as Director, then as Vice President, of Research, Drug Development and New Technologies at Biovail Corporation International (now Biovail Corporation), a drug delivery company. During this time, Professor Odidi developed several blockbuster drugs, including supergenerics of the very difficult to duplicate Adalat CC (Bayer) and Procardia XL (Pfizer).

In the pharmaceutical industry, Professor Odidi is highly regarded for his entrepreneurial acumen, something rare for a scientist. Professor Odidi is also a highly respected innovator and inventor with a long history of success. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles and textbooks.

Prior to 1995, Professor Odidi held senior positions in academia and in the pharmaceutical and health care industries. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.

Professor Isa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University, and his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England. Professor Odidi is a graduate of the highly regarded Western Executive Management Program at the Ivey School of Business, University of Western Ontario. Professor Isa Odidi has also recently obtained his MBA from the prestigious Rotman School of Business at the University of Toronto.

Professor Odidi's role in the company is to provide inventive approaches to drug formulation, strategic direction, managerial and scientific guidance, and to oversee the widest commercialization of the company's considerable scientific capabilities.